Revolution against Lyme disease: a new vaccine kills bacteria in ticks’ gut

A new vaccine targeting Lyme disease, developed by Pfizer and Valneva, shows 74% efficacy in trials and could be a significant preventive measure against this vector-borne infection. The European Medicines Agency is currently evaluating the vaccine, which works by generating antibodies that neutralize Borrelia bacteria in ticks before transmission to humans. Lyme disease, often misdiagnosed due to its nonspecific symptoms, poses challenges in treatment and surveillance. If approved, this vaccine could help combat the rising incidence of Lyme disease linked to climate change, as ticks expand their geographic range. Experts emphasize the importance of preventive measures, including proper clothing and tick checks after outdoor activities.